A regulatory shorthand with real technical consequences
“Good x Practice” is the expansion of GxP, with x serving as a variable for regulated pharmaceutical domains: manufacturing (GMP), laboratory (GLP), clinical (GCP), distribution (GDP), and pharmacovigilance (GVP). The term is a collective reference to the quality management frameworks that govern how pharmaceutical products are developed, manufactured, tested, stored, distributed, and monitored after market release.
The acronym appears everywhere in pharma compliance discussions, but its simplicity is misleading. Each GxP domain carries distinct regulatory requirements, different enforcement mechanisms, and different implications for software systems. A system that is compliant with GLP requirements is not automatically GMP-compliant — the domains overlap in principles but diverge in specifics. For engineering teams, this is the practical consequence: scoping work to “make it GxP” without naming the domain is the first step toward over-validating non-critical paths and under-validating critical ones.
The GxP domains mapped
| GxP | Full name | What it governs | Key software implication |
|---|---|---|---|
| GMP | Good Manufacturing Practice | Production, packaging, labelling, storage | Batch records, process control, environmental monitoring |
| GLP | Good Laboratory Practice | Non-clinical safety studies | Study data, sample tracking, instrument qualification |
| GCP | Good Clinical Practice | Clinical trials, human subject data | Randomisation, data capture, adverse event reporting |
| GDP | Good Distribution Practice | Storage and transport of finished products | Temperature monitoring, chain-of-custody, serialisation |
| GVP | Good Pharmacovigilance Practice | Post-market safety surveillance | Signal detection, case processing, periodic safety reports |
A software system enters GxP scope whenever it creates, modifies, stores, or transmits data relevant to any regulated domain. A laboratory information management system (LIMS) falls under GLP when supporting non-clinical studies and under GMP when supporting release testing. The same system may carry different GxP obligations depending on the data it processes — and a single PostgreSQL instance backing both flows inherits the stricter regime for each table it owns.
Why engineering teams need to understand GxP scope
Engineering teams repeatedly stumble by treating GxP as a system-level attribute instead of recognizing it as a characteristic of the data and processes that systems handle. A database server hosting both GMP batch records and non-GxP administrative data is not entirely GxP-relevant — but the GMP data it stores carries GxP obligations regardless of the system architecture. The boundary runs through the schema, not around the server.
This distinction matters for AI system deployment. A machine learning model that analyses pharmaceutical manufacturing data to suggest process optimisations is GxP-relevant if its suggestions influence quality-affecting decisions. The same model architecture — same PyTorch checkpoint, same ONNX export, same inference container — deployed for non-GxP applications (facility energy management, workforce scheduling) carries no GxP obligations. The model weights do not change; the regulatory weight attached to their outputs does.
We work through this scoping question explicitly at project kickoff, because the cost of getting it wrong runs in both directions. Over-scoping pulls auxiliary systems into validation programmes they do not need, slowing delivery for no compliance benefit. Under-scoping leaves quality-affecting outputs unvalidated and surfaces as an inspection finding months later.
The full compliance requirements for AI software under GxP depend on which specific GxP domain applies, what data the system processes, and whether the system’s outputs affect product quality or patient safety.
GxP is not a certification
No certificate exists that validates a company or system as “GxP compliant.” GxP compliance is a demonstrable state — maintained through validated processes, controlled documentation, qualified personnel, and ongoing quality oversight. Regulatory inspectors assess compliance by examining evidence: validation documentation, audit trails, change control records, training records, and deviation investigations.
A company claims GxP compliance for specific processes and systems, not for the organisation as a whole. An FDA inspector examining a manufacturing facility evaluates cGMP compliance for the specific products, processes, and systems within the inspection scope. A finding of non-compliance in one area does not invalidate compliance in unrelated areas — but it does trigger regulatory scrutiny that often expands the inspection scope, which is why isolated remediation is rarely as cheap as it first looks.
How do GxP requirements shape software architecture?
Why should engineering teams building pharmaceutical software understand GxP when Quality Assurance owns regulatory compliance? Because GxP requirements directly determine software architecture, development workflows, and deployment strategies. Because GxP requirements dictate software architecture, development processes, and deployment practices from the ground up. Because GxP mandates dictate architecture choices, development workflows, and how you deploy code. Not to own compliance—Quality Assurance handles that—but because these requirements determine software architecture, development workflows, and how code reaches production. Because GxP mandates reshape architecture, development workflows, and how you deploy code. The decisions land in code long before they land on a validation report.
Audit trail requirements (every data change must be logged with who, what, when, and why) affect database design, API design, and user interface design from the architectural level. Retrofitting audit trails into a system designed without them requires touching every data modification path — often a near-complete rewrite. The pattern we see most often: a team adds a last_modified_by column late in the project and discovers that half their write paths bypass the application layer entirely.
Electronic signature requirements (21 CFR Part 11) dictate authentication architecture, session management, and signing workflow design. A system where users “sign” by clicking an OK button without password re-entry does not meet regulatory requirements and will be flagged during inspection. The signing event must be cryptographically bound to the user, the record, the timestamp, and the meaning of the signature — four bindings, not one.
Change control requirements mean that every software update — including bug fixes, configuration changes, and dependency updates — must be assessed for GxP impact, documented, tested, and approved before deployment. This fundamentally changes the deployment cadence: regulated systems cannot adopt continuous deployment practices without a compliant change control wrapper. Teams that try to keep a daily release rhythm typically end up with a parallel “non-GxP track” for cosmetic changes and a slower track for anything that touches validated functionality, with explicit gating between them in their CI pipeline.
We train engineering teams on these requirements at project kickoff because discovering them mid-development forces expensive rearchitecting. A focused workshop covering audit trails, electronic signatures, data integrity requirements, and change control procedures saves weeks of rework later in the project.
ALCOA+ as the architectural thread
ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) form the data integrity foundation underlying every GxP software requirement. Every architectural decision should be evaluated against these principles:
- Attributable — does the system record who created or modified data, including service accounts running automated jobs?
- Legible — is data stored in formats that remain human-readable and machine-readable across the retention period (often 10+ years)?
- Contemporaneous — are timestamps generated automatically by the system at the moment of the event, rather than entered manually after the fact?
- Original — can the original record be distinguished from copies, exports, and derived analyses?
- Accurate — are there controls preventing unauthorised modification, and is the modification path itself audited?
These principles, rather than the specific regulation text, are the practical guide for engineering teams designing GxP-compliant systems. A team that internalises ALCOA+ early will make the right architectural choices without needing to re-read 21 CFR Part 11 every sprint. The rest of our life-sciences AI practice runs on that same early-internalisation habit.
FAQ
What does GxP compliance specifically require when the software is AI/ML rather than deterministic code?
Audit trails, electronic signatures, change control, and data integrity form the regulatory foundation, yet AI introduces two additional layers: model lifecycle management—covering training data lineage, versioning, and retraining triggers—alongside inference traceability linking each output to its precise model version and input. Deterministic code is validated once per release; an AI system is validated against a frozen model, and any model change is a change-control event.
Which GxP rules apply to AI training data, models, and inference outputs?
Training data inherits the GxP status of its source: data drawn from GMP batch records is GMP-relevant and must satisfy ALCOA+ in its training pipeline. Models that influence quality-affecting decisions are themselves GxP-relevant artifacts subject to versioning, change control, and validation evidence. Inference outputs that feed into release decisions, deviation investigations, or regulatory submissions must be auditable end-to-end — input, model version, output, and reviewer all linked.
How is a GxP-validated AI system kept compliant as the model retrains or drifts?
Through a documented model lifecycle that treats retraining as a controlled change. Each retraining event is preceded by a change assessment (does the new training data shift the model’s risk profile?), accompanied by performance validation against a held-out qualification set, and concluded with QA approval before deployment. Drift monitoring runs continuously, and a drift threshold breach triggers the change control process — it is not handled silently in production.
Where is the boundary between GxP and non-GxP usage of AI inside a pharma manufacturing workflow?
The boundary follows the data and the decision, not the system. An AI model that suggests process parameter adjustments to operators on the shop floor is GxP-relevant because its output influences a quality-affecting action. The same model architecture deployed to forecast utility consumption is not GxP-relevant. When a single deployment serves both purposes, the GxP regime applies to the GxP-relevant path end-to-end.
Which GxP roles (system owner, QA, validation lead) own AI-specific risks and how is that documented?
The system owner remains accountable for fitness-for-purpose and is the named owner of the AI system in the validation master plan. QA owns the compliance assessment and approves the validation strategy. A validation lead executes the protocol. AI-specific risks — training data drift, model degradation, explainability gaps — are typically documented in the system’s risk assessment with named owners for each mitigation, and reviewed at a defined cadence rather than only at release.
How do ISPE’s GAMP AI guidance and the ISPE AI maturity model fit into an existing GxP programme?
GAMP 5 (Second Edition) and the ISPE GAMP AI guidance extend the existing GAMP category framework to AI/ML systems, giving teams a structured way to classify AI software and scale validation effort to risk. The ISPE AI maturity model is an organisational self-assessment tool — useful for identifying capability gaps in governance, data management, and lifecycle controls, but not a replacement for system-level validation. Most teams use the maturity model to plan their programme and GAMP guidance to execute individual system validations within it.
GxP as a shared vocabulary across regulatory domains
Documentation, traceability, and auditability unite all Good Practice frameworks across manufacturing and clinical environments. Revisit it when your workload shifts.
